Citation Impact
Citing Papers
Global Cancer Incidence and Mortality Rates and Trends—An Update
2015 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States
2016
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
2015
Cancer Statistics, 2021
2021 Standout
The Effect of Concurrent Human Immunodeficiency Virus Infection on Chronic Hepatitis B: A Study of 150 Homosexual Men
1989
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study
2015
Regulation of microRNA function in animals
2018 Standout
Hepatitis B Virus Infection — Natural History and Clinical Consequences
2004 Standout
Molecular diagnosis and treatment of drug-resistant hepatitis B virus
2014
To err (meiotically) is human: the genesis of human aneuploidy
2001 Standout
Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment
2013
Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis
2013
Non-alcoholic fatty liver disease – A global public health perspective
2018 Standout
Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA
2014
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy
2015
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
2016
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’
2014
Trisomy Recurrence: A Reconsideration Based on North American Data
2004
Burden of liver diseases in the world
2018 Standout
Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection
2015
Hepatitis C
2015
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
2017
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma
2017
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?
2015
Counting cross-overs: characterizing meiotic recombination in mammals
2000
The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus
2014 StandoutNobel
Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients With Chronic Hepatitis B
2012
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
2018
Direct-acting antiviral agents for HCV infection affecting people who inject drugs
2017
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily
2012
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
2017
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination
2015
Non-alcoholic fatty liver disease
2021 Standout
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
2014
Management of treatment failure in chronic hepatitis B
2012
Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients
2012
Chronic hepatitis B
2007 Standout
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
2015 StandoutNobel
Chronic hepatitis B: Update 2009 #
2009 Standout
Optimal management of hepatitis B virus infection – EASL Special Conference
2015
Direct and Indirect Economic Burden of Chronic Liver Disease in the United States
2016
Global burden of liver disease: 2023 update
2023 Standout
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines
2013
Efficacy of Tenofovir Disoproxil Fumarate At 240 Weeks in Patients With Chronic Hepatitis B With High Baseline Viral Load
2013
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
2014
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure
2016
Effect of HCV clearance with direct-acting antiviral agents on HCC
2016
Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B
2013
Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life
2013
Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
2014
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
2003 Standout
Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta
2014
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study
2014
Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk?
2014
Recurrent miscarriage
2006 Standout
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
2015
Effect of Virological Response to Entecavir on the Development of Hepatocellular Carcinoma in Hepatitis B Viral Cirrhotic Patients: Comparison Between Compensated and Decompensated Cirrhosis
2014
Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
2014
Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection
2013
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
2016
Update in the management of chronic hepatitis B
2013
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice
2015
Hepatocellular carcinoma
2022 Standout
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany
2015
Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response.
2006
Lithium-related genetics of bipolar disorder
2001
Prediction of risk for hepatocellular carcinoma by response of serum α‐fetoprotein to entecavir therapy
2015
Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
2015
Hepatocellular Carcinoma
2019 Standout
Immunological Surveillance of Tumors in the Context of Major Histocompatibility Complex Restriction of T Cell Function
1984 StandoutNobel
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
2014
AASLD guidelines for treatment of chronic hepatitis B
2015
Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance
2013
Changes of HBsAg and HBV DNA levels in C hinese chronic hepatitis B patients after 5 years of entecavir treatment
2013
Therapy for hepatitis C genotype 3: moving forward
2015
Protease inhibitor therapy for hepatitis C virus-infection
2018
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
2017 Standout
Entecavir plus tenofovir combination therapy in patients with multidrug‐resistant chronic hepatitis B : results of a multicentre, prospective study
2016
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1
2019 StandoutNobel
Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B
2014 StandoutNobel
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial
2015
Seed Sequence-Matched Controls Reveal Limitations of Small Interfering RNA Knockdown in Functional and Structural Studies of Hepatitis C Virus NS5A-MOBKL1B Interaction
2014 StandoutNobel
Antiviral treatment and liver‐related complications in hepatitis delta
2016
Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?
2017
Screening for Hepatitis C Virus Infection in Adolescents and Adults
2020
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
2012
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy
2016
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD
2020
GSK-3: tricks of the trade for a multi-tasking kinase
2003 Standout
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus–infected patients treated with direct‐acting antivirals
2017
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
2015
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Transformation Induced by Herpes Simplex Virus: A Potentially Novel Type of Virus-Cell Interaction
1981
Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions
2017
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Global cancer statistics, 2012
2015 Standout
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues
2012
Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.
2002
Management of patients with hepatitis B in special populations
2015
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
2013
Works of Ashley Brown being referenced
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
2017
Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection
2015
Response to antiviral therapy in patients with genotype 3 chronic hepatitis C
2011
Genome-wide variation in recombination in female meiosis: a risk factor for non-disjunction of chromosome 21
2000
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
2011
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials
2016
Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
2014
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
2016
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
2016
Expression of type C virus p30 in mouse cells infected with herpes simplex virus
1977
Spontaneous loss of HBeAg and the prevalence of HTLV-III/LAV infection in a cohort of homosexual hepatitis B virus carriers and the implications for antiviral therapy
1986
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH ‐C) patients: an economic model from five European countries
2015
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
2012
Elevated platelet membrane phosphatidylinositol-4,5-bisphosphate in bipolar mania
1993
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study
2017
2012
LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study
2015
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study
2011
869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial
2013